Iranian Red Crescent Medical Journal

Published by: Kowsar

The Effect of 17α-Hydroxyprogesterone Caproate on Prevention of Preterm Labor in High-Risk Pregnant Women

Shole Shahgheibi 1 , Nazli Hamrah 1 , * , Nasrin Soofizadeh 1 , Aidin Mojtahedzadeh 2 , Fariba Seyedoshohadaei 1 , Masomeh Rezaie 1 and Ghobad Moradi 3
Authors Information
1 Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
2 Department of Pathology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
3 Department of Epidemiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: February 01, 2016, 18 (2); e26150
  • Published Online: February 20, 2016
  • Article Type: Research Article
  • Received: January 6, 2015
  • Revised: June 16, 2015
  • Accepted: January 2, 2016
  • DOI: 10.5812/ircmj.26150

To Cite: Shahgheibi S, Hamrah N, Soofizadeh N, Mojtahedzadeh A, Seyedoshohadaei F, et al. The Effect of 17α-Hydroxyprogesterone Caproate on Prevention of Preterm Labor in High-Risk Pregnant Women, Iran Red Crescent Med J. 2016 ; 18(2):e26150. doi: 10.5812/ircmj.26150.

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Cunningham FG, Leveno KJ, Bloom SL, Hauth J, Gilstrap L, Wenstrom K. Williams obstetrics. 22nd. 2005; 987: 804-17
  • 2. Vidaeff AC, Ramin SM. Management strategies for the prevention of preterm birth. Part I: Update on progesterone supplementation. Curr Opin Obstet Gynecol. 2009; 21(6): 480-4[DOI][PubMed]
  • 3. Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev. 2012; 12[DOI][PubMed]
  • 4. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005; 193(3 Pt 2): 1127-31[DOI][PubMed]
  • 5. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol. 2003; 102(3): 488-92[PubMed]
  • 6. Petrou S, Mehta Z, Hockley C, Cook-Mozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital inpatient admissions and costs during the first 5 years of life. Pediatrics. 2003; 112(6 Pt 1): 1290-7[PubMed]
  • 7. Bloom SL, Yost NP, McIntire DD, Leveno KJ. Recurrence of preterm birth in singleton and twin pregnancies. Obstet Gynecol. 2001; 98(3): 379-85[PubMed]
  • 8. Rust OA, Bofill JA, Arriola RM, Andrew ME, Morrison JC. The clinical efficacy of oral tocolytic therapy. Am J Obstetr Gynecol. 1996; 175(4): 838-42[DOI]
  • 9. Levine L. Habitual abortion. A controlled clinical study of presentational therapy. West J Surg. 1964; 72: 30-6
  • 10. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Lib. 2004;
  • 11. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999; 14(8): 1944-8[PubMed]
  • 12. Gallagher K. Progesterone for preventing preterm labor and delivery. Am College Obstetricians Gynecol Obstetr Gynecol. 2003; 102: 1115-6
  • 13. Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyl progesterone treatment during pregnancy. Congenital Anomalies. 2006; 46: 194-8
  • 14. Danforth DN, Gibbs RS. Danforth's obstetrics and gynecology. 2008;
  • 15. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348(24): 2379-85[DOI][PubMed]
  • 16. Pessel C, Moni S, Zork N, Brubaker S, Vink J, Fuchs K, et al. The effect of intramuscular progesterone on the rate of cervical shortening. Am J Obstet Gynecol. 2013; 209(3): 269 e1-7[DOI][PubMed]
  • 17. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening G. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007; 357(5): 462-9[DOI][PubMed]
  • 18. Fontenot HB, Fantasia HC. Vaginal progesterone to prevent preterm birth in high-risk women. Nurs Womens Health. 2012; 16(3): 237-41[DOI][PubMed]
  • 19. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007; 30(5): 687-96[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments